Fine Foods & Pharmaceuticals N.T.M. SpA stock analysis
Want to see IT:FF full AI Analyst Report?
Strong TTM revenue growth indicates that Fine Foods is expanding its volume of contracted pharmaceutical and nutraceutical work. If sustained, a larger revenue base can improve capacity utilization, support operating leverage, and strengthen the company’s ability to absorb fixed manufacturing and compliance costs.
Resilient operating cash flow provides an important foundation for the business despite weaker reported earnings. Continued cash generation from core operations can help fund production activities, quality investments, and customer programs while reducing reliance on external financing for routine needs.
Fine Foods operates across several connected CDMO activities rather than only producing finished products. Combining manufacturing with packaging, industrialization, and quality or regulatory support can deepen client integration, broaden revenue opportunities, and make the service relationship more strategically useful over time.
The sharp gross-margin decline and return to a net loss indicate that revenue growth is not currently translating into stronger earnings. Persistent cost, pricing, mix, or financing pressure would reduce internal funding capacity and make future profitability more dependent on operational improvement.
Higher debt alongside lower equity has materially reduced balance-sheet flexibility. With debt-to-equity rising to about 0.67, more cash may be required for financing obligations, leaving less room to withstand prolonged margin pressure or fund growth initiatives without additional borrowing.
Operating cash flow is not converting consistently into free cash flow after reinvestment and capital needs. Thin and volatile surplus cash limits the company’s ability to reduce debt, sustain distributions, or finance expansion internally, increasing sensitivity to execution and working-capital demands.
Analyst Giorgio Tavolini of Intermonte maintained a Buy rating on Fine Foods & Pharmaceuticals N.T.M. SpA, retaining the price target of €13.00. Giorgio Tavolini has given his Buy rating due
Giada Cabrino, an analyst from Intesa Sanpaolo, maintained the Buy rating on Fine Foods & Pharmaceuticals N.T.M. SpA. The associated price target is €12.80. Giada Cabrino has given her Buy
Analyst Giorgio Tavolini of Intermonte maintained a Buy rating on Fine Foods & Pharmaceuticals N.T.M. SpA, boosting the price target to €12.00. Giorgio Tavolini has given his Buy rating due
Fine Foods & Pharmaceuticals N.T.M. SpA (FF – Research Report), the Consumer Defensive sector company, was revisited by a Wall Street analyst on March 14. Analyst Giorgio Tavolini from Intermonte
Fine Foods & Pharmaceuticals N.T.M. S.p.A. functions as a contract development and manufacturing organization (CDMO), specializing in the creation of various oral solid forms for the pharmaceutical and nutraceutical sectors. Its pharmaceutical offerings include items such as powders, granules, capsules, standard and film-coated tablets, effervescent granules, and hard gelatine capsules. For the nutraceutical market, the company produces soluble, effervescent, and chewable tablets, fast-melting/sublingual tablets, film-coated tablets, and hard gelatine capsules, alongside soluble and effervescent powders and granules. These nutraceutical products are designed to support a wide range of health needs, encompassing areas like probiotics, multivitamins and minerals, immune system function, sleep and relaxation, gastrointestinal and circulatory health, osteoarticular and urinary systems, women's health, beauty, healthy aging, and mental wellbeing. In addition to its core CDMO services, the company also manufactures and sells a diverse array of cosmetic products, covering hair care, skin care, liquid personal hygiene items, oral hygiene products, deodorants, alcohol-based perfumery, bath and shower gels, shampoos and conditioners, shaping waxes, mouthwashes, creams, gels, and toothpastes. Furthermore, they supply medical surgical aids and devices, various antiseptics for intact skin, hand sanitizers, pre-injection solutions, hydroalcoholic surface cleaners, and iodine. Their product line also extends to orthodontic cleaning tablets, disinfectants, and decongestant nasal sprays. Established in 1984, the company is headquartered in Verdellino, Italy.
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 3 | 15 |
| Technical Analysis | 4 | 3 | 3 |
| Moving Averages | 0 | 0 | 12 |
